Clinical study of mesenchymal stem cells prophylactic sequential infusion to reduce GVHD after unrelated donor peripheral blood stem cell transplantation for patients with severe ß-thalassemia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050334

Enrollment

Unknown

Registered

2021-08-26

Start date

2021-08-22

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe ß-Thalassemia

Interventions

Experimental group:MSCs infusion

Control group:Conventional therapy

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1.Consistent with the diagnosis of severe ß-thalassemia; 2.Aged 2 to 16 years, male or female; 3.Unrelated donor hematopoietic stem cell transplantation; 4.ECOG score <= 1, people with follow-up conditions.

Exclusion criteria

Exclusion criteria: 1.Severe insufficiency of heart, lung, liver, kidney and other important organs; 2.Investigator evaluation of other reasons for non-inclusion.

Design outcomes

Primary

Measure	Time frame
acute graft versus host disease;complete remission;partial remission;no remission;progress;	—

Countries

China

Contacts

Public ContactZhang Xi

The Second Affiliated Hospital of Army Medical University

zhangxxi@sina.com+86 23 68763198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026